ArticleCureus2026
A Rare Case of Solitary Brain Metastasis From Papillary Thyroid Carcinoma: The Role of Empiric I-131 Therapy and SPECT/CT (Single Photon Emission Computed Tomography/Computed Tomography) in Achieving an 11-Year Survival.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain metastases from papillary thyroid carcinoma (PTC) are rare and typically associated with a poor prognosis; however, early detection of solitary lesions can lead to exceptional long-term outcomes. We present the case of a 65-year-old man with a history of multicentric PTC (T1bN0M0, Stage I) treated with total thyroidectomy and postoperative radioiodine ablation 12 years earlier, who presented with rising thyroglobulin (Tg) levels (12 ng/mL) under TSH (thyroid-stimulating hormone) stimulation. Neck ultrasonography and 18F-FDG PET/CT (18-fluorodeoxyglucose positron emission tomography/computed tomography) failed to identify recurrent disease. Empiric high-dose (150 mCi; 5.55 GBq) I-131 therapy was administered. Post-therapy, whole-body imaging demonstrated focal cranial uptake, initially suspected as contamination. I-131 SPECT/CT (single photon emission computed tomography/computed tomography) fusion imaging localized intense iodine uptake to the right occipital lobe. A cranial MRI confirmed a 15 × 15 mm enhancing lesion. The patient underwent craniotomy, and histopathological evaluation confirmed metastatic PTC with follicular features. Immunohistochemistry was positive for TTF-1 and thyroglobulin, with a Ki-67 proliferation index of 20%. The patient remains clinically and biochemically stable and disease-free 11 years after the metastasectomy, demonstrating an exceptionally long survival period for brain metastasis from PTC. This case highlights the diagnostic value of empiric high-dose radioiodine therapy combined with SPECT/CT in detecting occult metastases. Furthermore, the 11-year disease-free survival in our patient underscores that early identification and surgical resection of solitary brain metastases from PTC can lead to an exceptionally favorable long-term prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.